DOCSLIB.ORG

Gene Expression of Nerve Growth Factor in the Developing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Expression of Nerve Growth Factor in the Developing N b'tr .q)_ GENE EXPRESSION OF NERVE GROWTH FACTOR IN THE DEVELOPING SPONTANEOUSLY HYPERTENSIVE RAT A Thesis submitted to the University of Adelaide in fulfrlment of the requirements for the degree of Doctor of Philosophy ln The Department of Clinical and Experimental Pharmacology, University of Adelaide by Patrick Helmer James Falckh B.Sc.(Hons.) February 1992 LIST OF PUBLICATTONS IN SUPPORT OF THTS THESIS Falckh PHJ, Irvine R, Rush R, Bridges D and Head RJ, 1989, Gene Expression of Nerve Growth Factor in the Mouse Salivary Gland, Clin. Exp. Pharmacol. Physiol., (Suppl. 16); Falckh PHJ, Rush R, Bridges D and Head RJ, 1990, Expression of Nerve Growth Factor (NGÐ and NGF-mRNA, Blood Vessels, YoL27(l):36: Falckh PHJ, Harkin LA and Head RJ, Expression of NGF in the Hea¡t and Kidney in the Developing Spontaneously Hypertensive Rat, Clin. Exp. Pharmacol Physiol., (in press); Falckh PHJ, Harkin LA and Head RJ, Resistance Vessel Gene Expression of Nerve Growth Factor is Elevated in Young Sponøneously Hypertensive Rats, Hypertension, (submitted 199 1) ll ACKNOWLEDGMENTS There are so many individuals to whom I would like to express my sincere gratitu"de for their help and support during my PhD. candidature that the list is far too long to include here, however, there are several who I feel I must mention. Professor Richard John Head, not only provided me the opportunity to conduct my studies at the CSIRO, Division of Human Nutrition, but arranged a scholarship with CSIRO, and provided the impetus of the project. Thanlcs to Mark Mano for hís friendship, discussions, support and technical adt,i¡B over the last 5 years and to many of the staff at CSIRO who provided technícal help and friendship especíally Roger King, Colin Chandler, Yvette Schaeffer and lan Pannent. David Courøge for his uncanny ability to "pull-a-rat-ont-of-a-hat", his wasted weekends and forbearance of the extensive breeding program I required over the years. Kath llles and Pat Nayda for their advíce, friendshíp and the annoyance I must have caused wíth interuuptions to have my thesis, and drafts, printed. Diana Bridges for her technical expertise in conducting the NGF determinations and Professor Robert (Bob) Rush for allowing the use of his laboratory for this work. My most sincerest thanlcs to Dr Mavis Abbey, CSIRO, Divisíon of Hwnan Nutrition, for her expert discussiotts and assistance in understanding molecular biology, her willingness to guide a confused mínd and the "lost deys" of reading my thesis. To many members of the Department for theír friendship, stimulating discussions and elbow-bending especially Rod lrvine, Gordon Crabb and Julie Jonsson. To Sotiria Bexis who has kept me sane (?) throughout my postgrad years with her unwavering friendship and loyalty,for the hours and days I "bent her ears",for the discussions we have shared and to whom the completion of this thesis is attributed for never letting me quit; I owe my greatest thanks and appreciatíon. Finally to my wift, Heather, and her family for their encouragement and support during the dfficult months of writing the thesis; especially for my bad moods. ThIs thesis is dedicated to my mother, who unfortunately did not see me complete my Universiry studies, but whom I love and miss greatly. lu ABSTRACT Hypemoradrenergic innervation of the vasculature is a recognised as a key characteristic in the spontaneously hypertensive rat (SHR), a genetic animal model of hypertension. Nerve growth factor (NGF), a protein essential for the development and maintenance of sympathetic innervation, has been shown to be elevated in the young SHR when compared to the normotensive conEol, the Wistar-Kyoto (WKY) rat. NGF concentrations have been shown to correlate with gene expression for the protein and with the degree of sympathetic innervation in many species. The NGFmRNA levels in cardiovascular tissue of neonatal, and developing, SHR and WKY rats were investigated to determine if there is a link between the gene expression of NGF and the pattern of abnormal sympathetic innervation in this model. The reliability of the cDNA probe used for the determination of NGFmRNA concentrations was initially verified by investigating NGFmRNA concentrations in the submaxillary salivary gland of the mouse after pharmacological manipulation. Mesenteric and caudal arteries of the SHR were found to contain significantly elevated levels of NGFmRNA (> 5 fold) consistent with the hypernoradrenergic state reported for these blood vessels. The kidney of the SHR also displayed an elevaæd NGFmRNA production, consistent with the elevated innervation reported for this tissue. Cardiac and aortic tissues, which do not exhibit hypernoradrenergic innervation in the SHR, displayed low levels of NGFmRNA which were generally similar to levels seen in cardiac and aortic tissues from V/KY rats. In the hypernoradrenergically lv innervared tissues the NGFmRNA levels were elevated as early as 2 days of age and the elevated level sustained for 6 weeks. The laner period corresponds to the normal time course for sympathetic innervation of the vasculature. It is proposed that the elevated degree of innervation seen in resistance vessels and organs (for example in the kidney) is due, in part, to a sustained elevation of NGFmRNA and that the elevated NGFmRNA is present at bifih. The findings also provide a rational basis for the elevated noradrenaline (NA) content of vessels in the SHR, the larger releasable pool of NA in the SHR and the elevated levels of NGF peptide in vessels from the SHR. The results provide sufficient stimulus for examination of a role of NGF in the initiation of hypertension in the SHR. v ABBREVIATIONS USED IN THIS THESIS o wall sÍess 32P 32Phosphorus 6-OHDA 6-hydroxydopamine Ad adrenalin Azso absorbance at 750nm ABS Australian Bureau of Statistics BC back cross BC2 second generation back cross bp base pairs BP blood pressure BSA bovine serum albumin cDNA complemenøry DNA cm centimeüe CNS cennal nervous system cpm counts per minute CsCl cesium chloride oc degrees celsius DPH dopamine p-hydroxylase dATP 2'-deoxyadenosine triphosphate DBP diastolic blood pressure dCTP 2' -deoxy cytidine triph o sph ate DEPC diethyl pyrocarbonate vi dGTP 2'-deoxyguanosine triphosphate DNA deoxyribonucleic acid dNTP deoxyribonucleotide triphosphates DOCA deoxycorticosterone acetate DR Dahl salt-resistant strain DS Dahl salt-sensitive strain dTTP 2'-deoxythymidine triphosphate ECso concentration required to produce 50 percent of the maximum response ECD elecEochemical detection EDTA ethylenediameteEa acetic acid EtBr ethidium bromide Fl first generation progeny F2 second generation progeny g grams I gravity unis GH Genetically hypertensive strain H/BW heart to body weight ratio HPLC high performance liquid chomatography hrs hours kb kilo base pairs LH Lyon hypertensive strain LL Lyon low blood pressure strain LN Lyon normotensive strain M moles per litre mg milligrams vll MHS Milan hypertensive strain min mlnute rnl millilitre Inm millimetres mM millimoles per liue mmHg millimetres of mercury MNS Milan normotensive strain MOPS 3-[N-morpholino] propane sulfonic acid NA noradrenaline NaOH sodium hydroxide ng nanogT¿un NGF nerve growth factor NGFrnRNA NGF messenger RNA NGF-R-mRNA NGF receptor m€ssenger RNA NGF-Rt NGF receptor NHF National Heart Foundation nm nanometre P Eansmural pressure PCA perchloric acid pmol picomoles r radius RNA ribonucleic acid rpm revolutions per minute SBH Sabra hypertensive strain SBN Sabra normotensive strain SBP systolic blood pressure viii SDW sterile distilled water sec seconds SEM standa¡d error of the mean SHR Spontaneously Hyperten sive Rat SHRSP SHR-stroke prone strain SMC smooth muscle cells SNA sympathetic nervous activity SNS sympathetic nervous system Soln 4 homogenising solution Soln D denaturing solution SSC standa¡d sodium/citrate buffer TAE tris-acetateÆDTA buffer l¡g mrcrogram pl microlitre ¡rM micromoles per litre V volts VSM vascular smooth muscle w wall thickness WKY Wistar Kyoto Rat x multiply lx CONTENTS DECLARATION LIST OF PUBLICATIONS IN SUPPORT u ACKNOWLEDGMENTS iï ABSTRACT iv ABBREVIATIONS vi CONTENTS x CHAPTER I : GENERAL INTRODUCTION I I.l Hypertension I I.1.1 Definition 1 1.1.2 Aetiology of Essential Hypertension 4 I.1.3 Genetic Hypertension 5 I.1.4 Sympathetíc Nervous System 6 I.I.5 Structural Changes 1 3 1.2 Animal Models of Hypertension l5 I.2.1 Spontaneously Hypertensive Rat 16 l.2.l.l Hypernoradrenergic Innervation 19 1.2.1.2 Structural Changes 23 I.3 Nerve Growth Factor 25 1.4 Introduction Summary 35 I.5 Aims 36 x CHAPTER II : GENERAL METHODS 37 II.] Glassware and Solutions 37 ll^z Gel Electrophoresis 37 Il.2.l Equipment 38 1L2.2 RNA Electrophoresis 38 11.2.2.1 Buffers 39 11.2.2.2 Gel Preparation 39 11.2.2.3 Sample Preparations q 11.2.2.4 Visualísation û II.2.3 DNAElectrophoresis 43 11.2.3.I Buffers 43 11.2.3.2 Gel Preparatíon 43 11.2.3.3 Sample Prepøratiort M 11.2.3.4 Visualisation M II.3 NorthernTransfers 45 II.4 Slot Blots 45 ll.4.l Sample Preparation 46 I1.4,2 Sample Application 46 II.5 The cDNA Probe 47 il.5.1 NGFrr¡RNA Probe Production 4t II.6 Radiolabelling of the cDNA Probe 52 II.6.1 NickTranslation 52 lL7 Hybridisation of Nitrocellulose Filters 56 lI.7.l Prehybridisation 56 1I.7.2 Hybridisation 57 1I.7.3 Stríngency Washes 59 II.8 Autoradiography 59 II.9 DNA Determinations 60 u.r0 Protein Determinations 60 xl CHAPTER III : ISOLATION OF RNA USING GUANIDINIUM- PHENOL.CHLOROFORM METHODOLOGIES 62 IfI.l Introduction 62 III.2 Isolation of RNA 63 III.2.1 The Chomczynski-Sacchi Method 63 lll.2.l.l
Load more

Recommended publications
  • Genome-Wide Identification of Brain Mirnas in Response to High
    Zhao et al. BMC Molecular Biol (2019) 20:3 https://doi.org/10.1186/s12867-019-0120-4 BMC Molecular Biology RESEARCH ARTICLE Open Access Genome‑wide identifcation of brain miRNAs in response to high‑intensity intermittent swimming training in Rattus norvegicus by deep sequencing Yanhong Zhao1*†, Anmin Zhang2,3*†, Yanfang Wang4, Shuping Hu3, Ruiping Zhang2 and Shuaiwei Qian2 Abstract Background: Physical exercise can improve brain function by altering brain gene expression. The expression mecha- nisms underlying the brain’s response to exercise still remain unknown. miRNAs as vital regulators of gene expres- sion may be involved in regulation of brain genes in response to exercise. However, as yet, very little is known about exercise-responsive miRNAs in brain. Results: We constructed two comparative small RNA libraries of rat brain from a high-intensity intermittent swim- ming training (HIST) group and a normal control (NC) group. Using deep sequencing and bioinformatics analysis, we identifed 2109 (1700 from HIST, 1691 from NC) known and 55 (50 from HIST, 28 from NC) novel candidate miRNAs. Among them, 34 miRNAs were identifed as signifcantly diferentially expressed in response to HIST, 16 were up- regulated and 18 were down-regulated. The results showed that all members of mir-200 family were strongly up- regulated, implying mir-200 family may play very important roles in HIST response mechanisms of rat brain. A total of 955 potential target genes of these 34 exercise-responsive miRNAs were identifed from rat genes. Most of them are directly involved in the development and regulatory function of brain or nerve.
    [Show full text]
  • Growth Cone Responses to Growth and Chemotropic Factors
    European Journal of Neuroscience European Journal of Neuroscience, Vol. 28, pp. 268–278, 2008 doi:10.1111/j.1460-9568.2008.06327.x Growth cone responses to growth and chemotropic factors Staci D. Sanford,1 Jesse C. Gatlin,1,* Tomas Ho¨kfelt2 and Karl H. Pfenninger1 1Departments of Pediatrics, and of Cell and Developmental Biology, and Neuroscience Program, University of Colorado School of Medicine, and University of Colorado Cancer Center, Aurora, CO 80045, USA 2Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden Keywords: attractants, axonal pathfinding, growth cone, growth promotion, neuropeptides, repellents Abstract During nervous system development axons reach their target areas under the influence of numerous guidance cues that affect rate and direction of growth. This report addresses the unsettled question of whether and to what extent growth velocity and turning responses (attraction, repulsion) are interdependent. We exposed individual growth cones of fetal rat dorsal root ganglion neurons in culture asymmetrically to gradients of seven different factors and recorded their growth rates and turning angles. Growth cones exhibited divergent patterns of turning and growth responses. For example, hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1) and thrombin all promoted growth, but HGF was a powerful attractant, thrombin a potent repellent and IGF-1 did not elicit turning. Galanin and neuropeptide Y also affected growth and ⁄ or turning differentially. Finally, nerve growth factor in the culture
    [Show full text]
  • Permeability Due to Drug Binding Kinetics and Reactivation Among
    Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability This information is current as of September 26, 2021. Mohammad Fallahi-Sichani, JoAnne L. Flynn, Jennifer J. Linderman and Denise E. Kirschner J Immunol 2012; 188:3169-3178; Prepublished online 29 February 2012; doi: 10.4049/jimmunol.1103298 Downloaded from http://www.jimmunol.org/content/188/7/3169 Supplementary http://www.jimmunol.org/content/suppl/2012/02/29/jimmunol.110329 http://www.jimmunol.org/ Material 8.DC1 References This article cites 59 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/188/7/3169.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability Mohammad Fallahi-Sichani,*,1 JoAnne L.
    [Show full text]
  • REVIEW Estrogens and Atherosclerosis
    R13 REVIEW Estrogens and atherosclerosis: insights from animal models and cell systems Jerzy-Roch Nofer1,2 1Center for Laboratory Medicine, University Hospital Mu¨nster, Albert Schweizer Campus 1, Geba¨ude A1, 48129 Mu¨nster, Germany 2Department of Medicine, Endocrinology, Metabolism and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy (Correspondence should be addressed to J-R Nofer at Center for Laboratory Medicine, University Hospital Mu¨nster; Email: [email protected]) Abstract Estrogens not only play a pivotal role in sexual development but are also involved in several physiological processes in various tissues including vasculature. While several epidemiological studies documented an inverse relationship between plasma estrogen levels and the incidence of cardiovascular disease and related it to the inhibition of atherosclerosis, an interventional trial showed an increase in cardiovascular events among postmenopausal women on estrogen treatment. The development of atherosclerotic lesions involves complex interplay between various pro- or anti-atherogenic processes that can be effectively studied only in vivo in appropriate animal models. With the advent of genetic engineering, transgenic mouse models of atherosclerosis have supplemented classical dietary cholesterol- induced disease models such as the cholesterol-fed rabbit. In the last two decades, these models were widely applied along with in vitro cell systems to specifically investigate the influence of estrogens on the development of early and advanced atherosclerotic lesions. The present review summarizes the results of these studies and assesses their contribution toward better understanding of molecular mechanisms underlying anti- and/or pro-atherogenic effects of estrogens in humans. Journal of Molecular Endocrinology (2012) 48, R13–R29 Introduction circumstances, these hormones promote the develop- ment of atherosclerosis.
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Guidelines for Pharmacists Performing Clinical Interventions
    Guidelines for pharmacists performing clinical interventions PSA Committed to better health © Pharmaceutical Society of Australia Ltd. 2018 This publication contains material that has been provided by the Pharmaceutical Society of Australia (PSA), and may contain material provided by the Commonwealth and third parties. Copyright in material provided by the Commonwealth or third parties belong to them. PSA owns the copyright in the publication as a whole and all material in the publication that has been developed by PSA. In relation to PSA owned material, no part may be reproduced by any process except in accordance with the provisions of the Copyright Act 1968 (Cwth), or the written permission of PSA. Requests and inquiries regarding permission to use PSA material should be addressed to: Pharmaceutical Society of Australia, PO Box 42, Deakin West ACT 2600. If you would like to use material that has been provided by the Commonwealth or third parties, contact them directly. Disclaimer Neither the PSA, nor any person associated with the preparation of this document, accepts liability for any loss which a user of this document may suffer as a result of reliance on the document and, in particular, for: • use of the Guidelines for a purpose for which they were not intended • any errors or omissions in the Guidelines • any inaccuracy in the information or data on which the Guidelines are based or which is contained in them • any interpretations or opinions stated in, or which may be inferred from, the Guidelines. Notification of any inaccuracy or ambiguity found in this document should be made without delay in order that the issue may be investigated and appropriate action taken.
    [Show full text]
  • Plasma Steroid-Binding Proteins: Primary Gatekeepers of Steroid Hormone Action
    230 1 G L HAMMOND Steroid bioavailability 230:1 R13–R25 Review Open Access Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action Correspondence Geoffrey L Hammond should be addressed Departments of Cellular & Physiological Sciences and Obstetrics & Gynaecology, to G L Hammond University of British Columbia, Vancouver, British Columbia, Canada Email [email protected] Abstract Biologically active steroids are transported in the blood by albumin, sex hormone- Key Words binding globulin (SHBG), and corticosteroid-binding globulin (CBG). These plasma f albumin proteins also regulate the non-protein-bound or ‘free’ fractions of circulating f sex hormone-binding globulin steroid hormones that are considered to be biologically active; as such, they can be f corticosteroid-binding viewed as the ‘primary gatekeepers of steroid action’. Albumin binds steroids with globulin limited specificity and low affinity, but its high concentration in blood buffers major f testosterone fluctuations in steroid concentrations and their free fractions. By contrast, SHBG and f estradiol Endocrinology CBG play much more dynamic roles in controlling steroid access to target tissues and f glucocorticoids of cells. They bind steroids with high (~nM) affinity and specificity, with SHBG binding f progesterone androgens and estrogens and CBG binding glucocorticoids and progesterone. Both are f serine protease inhibitor Journal glycoproteins that are structurally unrelated, and they function in different ways that extend beyond their transportation or buffering functions in the blood. Plasma SHBG and CBG production by the liver varies during development and different physiological or pathophysiological conditions, and abnormalities in the plasma levels of SHBG and CBG or their abilities to bind steroids are associated with a variety of pathologies.
    [Show full text]
  • Theranostics R13 Preserves Motor Performance in SOD1G93A Mice By
    Theranostics 2021, Vol. 11, Issue 15 7294 Ivyspring International Publisher Theranostics 2021; 11(15): 7294-7307. doi: 10.7150/thno.56070 Research Paper R13 preserves motor performance in SOD1G93A mice by improving mitochondrial function Xiao Li1,2#, Chongyang Chen2#, Xu Zhan2#, Binyao Li3, Zaijun Zhang4, Shupeng Li5, Yongmei Xie6, Xiangrong Song7, Yuanyuan Shen8, Jianjun Liu1, Ping Liu2, Gong-Ping Liu2,9, Xifei Yang1 1. Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Medical Key Subject of Modern Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China. 2. Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Tianjin Institute of Pharmaceutical Research New Drug Assessment Co. Ltd, Tianjin 300301, China. 4. Institute of New Drug Research and Guangzhou, Key Laboratory of Innovative Chemical Drug Research in Cardio-Cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou 510632, China. 5. School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China. 6. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China. 7. Department of Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. 8. National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China. 9. Co-innovation Center of Neuroregeneration, Nantong University, Nantong, JS, China. #These authors contributed equally to this work.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • NIH Pediatrics Research Report FY2019
    DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Report to Congress: Pediatric Research in Fiscal Year 2019 September 2020 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Report to Congress: Pediatric Research in Fiscal Year 2019 TABLE OF CONTENTS Table of Contents ....................................................................................................................... i PEDIATRIC RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH................................... 1 NEW IN FY 2019 ...................................................................................................................... 1 THE PEDIATRIC RESEARCH INITIATIVE................................................................................ 2 SELECTED SCIENTIFIC RESEARCH ADVANCES IN PEDIATRICS ........................................... 3 Pregnancy and Newborn Health 3 Child Development 6 Social and Environmental Influences 7 Nutrition and Obesity 10 Diabetes 12 Childhood Diseases 13 Immunity and Allergies 17 Rare Pediatric Diseases 19 Pediatric Cancer 19 Bone and Muscle Health 23 Oral Health, Speech, Hearing, and Vision 25 Intellectual and Developmental Disabilities, Neurological Disorders, and Mental Health 26 Childhood Injuries, Maltreatment, and Violence 31 Substance Use and Misuse 32 Pediatric Critical Care and Emergency Care 35 Clinical Care, Outreach, and Services 37 Pediatric Pharmacology 38 Technology and Tools 39 Global Pediatric Health 40 SELECTED NEW AND EXPANDED RESEARCH EFFORTS FOR FY 2019 IN PEDIATRICS
    [Show full text]
  • Lllllllllllllllllllllllllllillllllllllllllllllllllllllllllll
    lllllllllllllllllllllllllllIlllllllllllllllllllllllllllllllllllllllllllllll 0500517515411 United States Patent [191 [11] Patent Number: 5,175,154 Schwartz et a1. [45] Date of Patent: Dec. 29, 1992 [54] 5 a-PREGNAN-ZO-ONES AND Malloux. et al., in Bulletin de la Societe Chemique de S-PREGNEN-ZO-ONES AND RELATED France. 617 (1969). COMPOUNDS Pouzar et a1. Chem. Abstracts 94:103670p ( 1980) “Ste [75] Inventors: Arthur G. Schwartz, Philadelphia; roids. Part CCXXXIV, Absolute Con?guration at C30 Marvin L. Lewbart, Media. both of of the Derivatives of 21-Nor-52-Cho1one-20,~ Pa. 24-Dio1“. Danilewicz et al., CA 62: 91936 1965. [73] Assignee: Research Corporation Technologies, Gravestock et a1. CA 92: 2156245 1980. Inc. Hanson, et al., Perkin Transactions 1, (1977), pp. [21] Appl. No; 126,310 499-501. Chemical Abstracts, 89. 1058656, (1978). [22] Filed: Nov. 25, 1987 Numazawa, et al., Steroids, 32. 519-527 (1978). [51] Int. C1.5 .................... .. A61K 31/58; A61K 31/56 (List continued on next page.) [52] 13.8. Cl. .................................. .. 514/172; 514/182; 514/909 [58] Field of Search ........................... .. 260/397, 397.5; Primary Examiner-Frederick E. Waddell 552/541-544, 546. 551-552. 554-556, 559-560, Assistant Examiner-Raymond J. Henley, Ill 562. 564. 565. 567-568. 582-583. 585, 589, 599, Attorney, Agent, or Firm—Scully, Scott, Murphy & 603-606, 609-616, 623-624, 650-652, 514. 536, Presser 537-539. 548: G23/182, 172 [56] References Cited [57] ABSTRACT US. PATENT DOCUMENTS Compounds of the formulae: 2.833.793 5/1958 Dodson et a1. ................... .. 514/178 2.911.418 11/1959 Johns et al.
    [Show full text]
  • Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Compr Physiol Manuscript Author . Author Manuscript Author manuscript; available in PMC 2020 July 07. Published in final edited form as: Compr Physiol. ; 10(1): 125–170. doi:10.1002/cphy.c190011. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure James Hester1, Corey Ventetuolo2,3, Tim Lahm*,1,4,5 1Department of Medicine, Division of Pulmonary, Allergy, Critical Care, Occupational and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA 2Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA 3Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA 4Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA 5Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA Abstract Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized by elevated pulmonary artery pressure and pulmonary vascular remodeling and that frequently lead to right ventricular (RV) failure and death. Several types of PH exhibit sexually dimorphic features in disease penetrance, presentation, and progression. Most sexually dimorphic features in PH have been described in pulmonary arterial hypertension (PAH), a devastating and progressive pulmonary vasculopathy with a 3-year survival rate <60%. While patient registries show that women are more susceptible to development of PAH, female PAH patients display better RV function and increased survival compared to their male counterparts, a phenomenon referred to as the “estrogen paradox” or “estrogen puzzle” of PAH. Recent advances in the field have demonstrated that multiple sex hormones, receptors, and metabolites play a role in the estrogen puzzle and that the effects of hormone signaling may be time and compartment specific.
    [Show full text]